| abstract |
The present invention relates to novel cdc25 phosphatase inhibitors, in particular to phosphatase cdc25-C inhibitors. The compounds are represented by the general formula (I) wherein the substituents have the following meanings: A is a group of formula wherein two of the groups R1, R2, R3, R4 and R5 are hydrogen, the other three are independently hydrogen, halogen, alkyl, hydroxy, alkoxy, alkylcarbonyloxy, alkylthio, or NR6R7, at each occurrence, R6 and R7 are independently hydrogen or alkyl, or R6 and R7 are taken together with the nitrogen atom to form a 4-7 membered heteroatom containing 1-2 heteroatoms, wherein the chain members required for heterocyclic addition are independently selected from the group consisting of -CR8R9-, -O-, -S- and -NR10-, wherein R8 and R9 are independently at each occurrence -H, or alkyl, alkoxy, benzyloxycarbonylamino, or dialkylamino; each occurrence alone independently H or alkyl, B is -CO-, -NH-CO- (CH 2) n - or - (CH 2) p - wherein n is an integer from 0 to 3 and p is an integer from 0 to 1; W is hydrogen or alkyl; X is - (CH 2) q -, - (CH 2) q -NH- or -CO- (CH 2) r - wherein q is an integer from 1 to 6 and r is an integer from 0 to 6. The invention also relates to salts of the listed compounds. A further object of the present invention is the use of a pharmaceutically acceptable salt of a compound of formula I for the preparation of a medicament for the inhibition of cdc25 phosphatases. SHE |